BIOCYTOGEN PHARMA. H YC1 Total Liabilities
BIOCYTOGEN PHARMA. H YC1 total liabilities. Based on the latest financial reports, BIOCYTOGEN PHARMA. H YC1 (I54) has total liabilities worth €1.54 Billion EUR (≈ $1.81 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are BIOCYTOGEN PHARMA. H YC1's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BIOCYTOGEN PHARMA. H YC1 (2021–2025)
Total liabilities of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025. This chart illustrates how BIOCYTOGEN PHARMA. H YC1's total liabilities have evolved over time, based on quarterly financial data.
BIOCYTOGEN PHARMA. H YC1 Competitors by Total Liabilities
The table below lists competitors of BIOCYTOGEN PHARMA. H YC1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vinte Viviendas Integrales S.A.B. de C.V
MX:VINTE
|
Mexico | MX$19.26 Billion |
|
Guangdong Hybribio Biotech Co Ltd
SHE:300639
|
China | CN¥475.29 Million |
|
Basler Kantonalbank
SW:BSKP
|
Switzerland | CHF51.12 Billion |
|
Ginkgo Bioworks Holdings
NYSE:DNA
|
USA | $569.76 Million |
|
Forrestania Resources Ltd
AU:FRS
|
Australia | AU$44.70 Million |
|
Canadian Tire Corporation Limited
TO:CTC
|
Canada | CA$14.73 Billion |
|
Hankuk Carbon
KO:017960
|
Korea | ₩463.75 Billion |
|
Xian Peri Power Semiconductor Cond
SHE:300831
|
China | CN¥61.50 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down BIOCYTOGEN PHARMA. H YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see I54 total asset value.
Liquidity & Leverage Metrics
BIOCYTOGEN PHARMA. H YC1 Total Liabilities Ratios Explained
BIOCYTOGEN PHARMA. H YC1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIOCYTOGEN PHARMA. H YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIOCYTOGEN PHARMA. H YC1 (2021–2025)
The table below shows the annual total liabilities of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.54 Billion ≈ $1.81 Billion |
-2.02% |
| 2024-12-31 | €1.58 Billion ≈ $1.84 Billion |
-4.96% |
| 2023-12-31 | €1.66 Billion ≈ $1.94 Billion |
+0.60% |
| 2022-12-31 | €1.65 Billion ≈ $1.93 Billion |
+56.93% |
| 2021-12-31 | €1.05 Billion ≈ $1.23 Billion |
-- |
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides th… Read more